VIVUS (VVUS) was Downgraded by WallachBeth to ” Hold”. Earlier the firm had a rating of “Buy ” on the company shares. WallachBeth advised their investors in a research report released on May 4, 2016.
On the company’s financial health, VIVUS reported $-0.12 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on May 3, 2016. Analyst had a consensus of $-0.11. The company had revenue of $15.32 million for the quarter, compared to analysts expectations of $17.97 million. The company’s revenue was down -52.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.15 EPS.
VIVUS closed down -0.07 points or -4.24% at $1.58 with 9,27,086 shares getting traded on Monday. Post opening the session at $1.63, the shares hit an intraday low of $1.56 and an intraday high of $1.655 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Apr 20, 2016, John L Slebir (SVP, Business Development & GC) sold 9,933 shares at $2.20 per share price. According to the SEC, on Apr 20, 2016, Guy P Marsh (VP, US Operations & GM) sold 633 shares at $3.04 per share price. On Apr 20, 2016, Wesley Day (VP, Clinical Development) sold 2,549 shares at $3.04 per share price, according to the Form-4 filing with the securities and exchange commission.
VIVUS Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic products. It provides two therapies approved by the Food and Drug Association (FDA) which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company is also developing and has completed the Phase II studies of Qsymia for the indication of OSA and diabetes. Qsymia is available in over 42000 certified retail pharmacies across the country. STENDRA is also approved by the European Commission (EC) under the name SPEDRA for the treatment of ED in the Europe. As of September 18 2014 the FDA approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.